Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
¹ ФГКУ «1586 военный клинический госпиталь» Минобороны РФ, Московская обл., г. Подольск, ул. Маштакова, тер. 4 ² ФГБУ МНИИП — филиал ФГБУ «НМИЦПН им. В.П. Сербского» МЗ РФ, г. Москва, ул. Потешная, д. 3 ³ ФГБУ ННЦН — филиал ФГБУ «НМИЦПН им. В.П. Сербского» МЗ РФ, г. Москва, ул. Ставропольская, д. 27, стр. 7 4 Кафедра психиатрии ФПДО, РНИМУ имени Н.И. Пирогова
Список исп. литературыСкрыть список 1. Kessler R.C., Bromet E.J. The epidemiology of depression across cultures // Ann. Rev. Public Health. 2013. Vol.34. P.119-138. 2. Mathews M., Gommoll C., Chen D. et al. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial // Int. Clin. Psychopharmacol. 2015. Vol.30. P.67-74. 3. Montgomery S.A., Nielsen R.Z., Poulsen L.H. et al. A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine // Hum. Psychopharmacol. 2014. Vol.29. P.470-482. 4. Florea I., Danchenko N., Brignone M. et al. The effect of vortioxetine on health-related quality of life in patients with major depressive disorder // Clin. Ther. 2015. Vol.37. P.2309-2232. 5. Elizabeth P., Tracy D.K. The drugs don’t work? antidepressants and the current and future pharmacological management of depression // Ther. Adv. Psychopharmacol. 2012. Vol.2. P179-188. 6. Быков Ю.В., Беккер Р.А., Резников М.К. Резистентные депрессии. Практическое руководство. Киев: Медкнига. 2013. 400 с. 7. Meltzer H.Y., Fang V.S., Tricou B.J. et. al. Effect of antidepressants on neuroendocrine axis in humans // Adv. Biochem. Psychopharmacol. 1982. Vol. 32. P. 303-316. 8. Fava G.A., Lisansky J., Buckman M.T. et. al. Prolactin, cortisol, and antidepressant treatment // Am J. Psychiatry. 1988. Vol. 145. N.3. P. 358-360. 9. Anderson I.M., Cowen P.J. Clomipramine enhances prolactin and growth hormone responses to L-tryptophan // Psychopharmacology (Berl). 1986. Vol. 89. N. 1. P. 131-133. 10. Electronic Medicines Compendium. Anafranil capsules: summary of product characteristics [online] // Available from URL: http://medicines.org.uk/emc [Accessed 2010, May 6]. 11. Hennings J.M., Schaaf L., Fulda S. Glucose metabolism and antidepressant medication // Curr. Pharm. Des. 2012. Vol. 18. P. 5900–5919. 12. Pan A., Sun Q., Okereke O.I. et al. Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults // Diabetologia. 2012. Vol. 55. P. 63–72. 13. Андрусенко М.П. Антидепрессанты: соотношение особенностей нейрохимического действия и клинических эффектов при лечении депрессий // Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2005. №5. С. 273-279. 14. Kivimäki M., Batty G.D., Jokela M. et al. Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? // Biol. Psychiatry. 2011. Vol. 70. P. 978–984. 15. Derijks H.J., Meyboom R.H.B., Heerdink E.R. et al. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports // Eur. J. Clin. Pharmacol. 2008. Vol. 64. P. 531– 538. 16. Khoza S., Barner J.C. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports // Int. J. Clin. Pharmacol. 2011. Vol. 33, P. 484–492. 17. Pyykkönen A.J., Räikkönen K., Tuomi T. et. al. Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: results from the PPP-Botnia Study // Ann. Med. 2012. Vol. 44. P. 279–288. 18. Andersohn F., Schade R., Suissa S. et. al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus // Am J. Psychiatry. 2009. Vol. 166. P. 591–598. 19. Павлова Т.А., Горобец Л.Н., Доровских И.В. и соавт. Изменение уровня пролактина в крови у пациентов с паническим расстройством при монотерапии пароксетином, кломипрамином и сочетанной терапии пароксетином с перициазином // Современная терапия психических расстройств. 2019. №2. С. 9-16. 20. Павлова Т.А., Горобец Л.Н., Доровских И.В. и соавт. Метаболические показатели у пациентов с паническим расстройством при монотерапии пароксетином, кломипрамином и сочетанной терапии пароксетином с перициазином // Социальная и клиническая психиатрия. 2019. Т.29. №3. С. 11-18. 21. Лычкова А.Э., Пузиков А.М. Пролактин и серотонин // Вестник РАМН. 2014. №1–2. C. 38-45. 22. Harrison W.M., Rabkin J.G, Ehrhardt A.A et al. Effects of antidepressant medication on sexual function: a controlled study // J. Clin. Psychopharmacol. 1986. Vol.6. P. 144-149. 23. Karp J.F, Frank E., Ritenour A. et al. Imipramine and sexual dysfunction during the long term treatment of recurrent depression // Neuropsychopharmacology. 1994. Vol.11. P.21-27. 24. Boyarsky B.K., Hirschfeld R.M. The management of medication-induced sexual dysfunction // Essent. Psychopharmacol. 2000. Vol.3. P. 39-58. 25. Monteiro W.O., Noshirvani H.F., Marks I.M. et al. Anorgasmia from clomipramine in obsessive-compulsive disorder: a controlled trial // Br. J. Psychiatry. 1987. Vol.151. P.107-112. 26. Rosen R.C., Lane R.M., Menza M. Effects of SSRIs on sexual function: a critical review // J. Clin. Psychopharmacol. 1999. Vol.19. P.67-85. 27. Strassberg D.S., De Gouveia Brazao C.A., Rowland D.L. et al. Clomipramine in the treatment of rapid (premature) ejaculation // J. Sex Marital Ther. 1999. Vol.25. P.89-101. 28. Rowland D.L., Tai W.L., Brummett K. et al. Predicting responsiveness to the tretment of rapid ejaculation with 25 mg clomipramine as needed // Int. J. Impot. Res. 2004. Vol.16. P.354-357. 29. Egberts A.C., Meyboom R.H., De Koning F.H. et. al. Nonpuerperal lactacion associated with antidepressant drug use // Br. J. Clin. Pharmacol. 1997. Vol. 44. N. 3. P. 277-281. 30. Seifritz E., Baumann P., Muller M.J. et. al. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males: a placebo-controlled evaluation of citalopram as 5-HT function probe // Neuropsychopharmacology. 1996. Vol. 14. N. 4. P. 253-263. 31. Kapitany T., Scindl M., Shindler S.D. et. al. The citalopram challenge test in patients with major depression and in healthy controls // Psychiatry Res. 1999. Vol. 88. N. 2. P. 75-88. 32. Mondelli V., Gianotti L., Picu A. et. al. Neuroendocrine effects of citalopram infusion in anorexia nervosa // Psychoneuroendocrinology. 2006. Vol. 31. N.10. P. 1139-1148. 33. Moeller O., Hetzel G., Rothermundt M. et. al. Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment // J. Psychiatr. Res. 2003. Vol. 37. N. 3. P. 261-262. 34. Isotani H., Kameoka K. Hypoglycemia associated with maprotiline in a patient with type 1 diabetes // Diabetes Care. 1999. Vol. 22. P. 862–863. 35. Sansone R.A., Sansone L.A. Driving on antidepressants: cruising for a crash? // Psychiatry (Edgmont). 2009. Vol. 6. P. 13–16. 36. Raeder M.B., Bjelland I., Emil Vollset S., Steen V.M. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study // J. Clin. Psychiatry. 2006. Vol. 67. P. 1974–1982. 37. Andersohn F., Schade R., Suissa S., Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus // Am J. Psychiatry. 2009. Vol. 166. P. 591–598. 38. Brown L.C., Majumdar S.R., Johnson J.A. Type of antidepressant therapy and risk of type 2 diabetes in people with depression // Diabetes Res. Clin. Pract. 2008. Vol. 79. P. 61–67. 39. Bhattacharya R., Ajmera M., Bhattacharjee S., Sambamoorthi U. Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults // Diabetes Res Clin Pract. 2014. Vol.105. N.2. P. 251-260. 40. Sambamoorthi U., Ma Y., Findley P.A., Rust G. Antidepressant use, depression, and new-onset diabetes among elderly Medicare beneficiaries // J Diabetes. 2013. Vol. 5. N.3. P. 327-335. 41. Herman J.B., Brotman A.W., Pollack M.H. et al. Fluoxetine-induced sexual dysfunction // J. Clin. Psychiatry. 1990. Vol.51. P. 25-27. 42. Patterson W.M. Fluoxetine-induced sexual dysfunction // J. Clin. Psychiatry. 1993. Vol.54. P. 71. 43. Montejo A.L., Llorca G., Izquierdo J.A. et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients // J. Clin. Psychiatry. 2001. Vol.62. P.10-21. 44. Gregorian R.S., Golden K.A., Bahce A. et al. Antidepressant-induced sexual dysfunction // Ann. Pharmacother. 2002. Vol.36. P.1557-1589. 45. Clayton A.H., Pradko J.F., Croft H.A. et al. Prevalence of sexual dysfunction among newer antidepressants // J. Clin. Psychiatry. 2002. Vol.63. P.357-366. 46. Ashton A.K., Mahmood A., Iqbal F. Improvements in SSRI/SNRI-induced sexual dysfunction by switching to escitalopram // J. Sex Marital Ther. 2005. Vol.31. P.257-262. 47. Reimherr F.W., Chuinard G., Cohn C.K. et al. Antidepressant efficacy of sertraline: a doubleblind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression // J. Clin. Psychiatry. 1990. Vol.51. P.18-27. 48. Benazzi F. Involuntary sperm emission with fluoxetine // Can. J. Psychiatry. 1995. Vol.40. P.431. 49. La Torre A. Il trattamento psicofarmacologico dell’eiaculazione precoce: analisi della letteratura // Rivista di Sessuologia. 1999. Vol.23. P.379-401. 50. Daffner-Bugia C., Laakmann G., Voberholzer U. et. al. The neuroendocrine effects of venlafaxine in healthy subject // Hum. Psychopharmacol. 1996. Vol. 11. P. 1-9. 51. Laakman G., Schule C., Baghai T. et. al. Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects // Psychoneuroendocrinology. 1999. Vol. 24. P. 769-784. 52. Laakman G., Schule C., Baghai T. et. al. Mirtazapine: an inhibitor of cortisol secretion that does not influence growth hormone and prolactin secretion // J. Clin. Psychopharmacol. 2000. Vol. 20. P. 101-103. 53. Schule C., Baghai T., Goy J. et. al. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects // Psychopharmacology (Berl). 2002. Vol. 163. P. 95-101. 54. Schule C., Baghai T., Laakman G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin in healthy male subject // Neuroendocrinology. 2004. Vol. 79. P. 54-62. 55. Khoza S., Barner J.C., Bohman T.M. et al. Use of antidepressant agents and the risk of type 2 diabetes // Eur. J. Clin. Pharmacol. 2012. Vol. 68. P. 1295–1302. 56. Khoza S., Barner J.C. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports // Int. J. Clin. Pharmacol. 2011. Vol. 33, P. 484–492. 57. Serretti A, Mandelli L: Antidepressants and body weight: a comprehensive review and meta-analysis // J. Clin. Psychiatry. 2010. Vol.71. P.1259–1272. 58. Kennedy S.H., Eisfeld B.S, Dickens S.E. et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine // J. Clin. Psychiatry. 2000. Vol.61. P. 276-281. 59. Serretti A., Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis // J. Clin. Psychoparmacol. 2009. Vol.29. P.259-266. 60. Altindag A. A case series of increased libido and spontaneous orgasm associated with venlafaxine treatment // Progress. Neuropsychopharmacol. Biol. Psychiatry. 2008. Vol.32. P.895-896. 61. Zahariou A., Papaioannou P., Karagiannis G. The efficacy of duloxetine in the treatment of premature ejaculation // Int. Urol. Nephrol. 2007. Vol.39. P.115-118. 62. Clayton A., Kornstein S., Prakash A. et al. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder // J. Sex. Med. 2007. Vol.4. P.917-929. 63. Nelson J.C., Pritchett Y.L., Martynorv O. et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials Prim. Care Companion // J. Clin. Psychiatry. 2006. Vol.8. P.212-219. 64. Saiz-Ruiz J., Montes J.M., Ibanez A. et al. Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study // Hum. Psychopharmacol. 2005. Vol.20. P.435-440. 65. Behnke K., Sogaard J., Martin S. et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study // J. Clin. Psychopharmacol. 2003. Vol.23. P.358-364. 66. Versiani M., Moreno R., Ramakers-van Moorsel CJ. A. et al. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients // CNS Drugs. 2005. Vol.19. P.137-146. 67. Wade A., Crawford G.M., Angus M. et al. A randomised, double-blind, 24-weekstudy comparing the efficacy and tolerability of mirtazepine and paroxetine in depressed patients in primary care // Int. Clin. Psychopharmacol. 2003. Vol.18. P.133-141. 68. Gelenberg A.J., McGahuey C., Laukes C. et al. Mirtazapine substitution in SSRI-induced sexual dysfunction // J. Clin. Psychiatry. 2000. Vol.61. P.356-369. 69. Хронобиологическая теория аффективных расстройств / под ред. С.Н. Мосолова. Москва: АВАНПОРТ. 2014. С.254-259. 70. Sansone R.A., Sansone L.A. Agomelatine: a novel antidepressant // Innov. Clin. Neurosci. 2011. Vol.8. N.11. P.10-14. 71. Chu Y.S., Shieh K.R., Yuan Z.F. et al. Stimulatory and entraining effect of melatonin on tuberoinfundibular dopaminergic neuron activity and inhibition on prolactin secretion // J. Pineal Res. 2000. Vol.28. N.4. P.219-226. 72. Bangalore Ravi P., Guruprasad K.G., Chittaranjan A. Unilateral Galactorrhea Associated with Low-dose Escitalopram // Indian J. Psychol. Med. 2014. Vol.36. N.3. P.344-345. 73. Hui Ling Tan. Agomelatine-induced gynaecomastia // Aust. N. Z. J. Psychiatry. 2013. Vol.47. N.12. P.1211-1212. 74. Горобец Л.Н., Ешелькина Е.Ю., Литвинов А.В. Взаимосвязь клинических показателей и уровня пролактина у больных с депрессивными расстройствами в процессе терапии антидепрессантами // Российский психиатрический журнал. 2009. №4. С. 92-98. 75. Carney R.M., Shelton R.C. Agomelatine for the treatment of major depressive disorder // Expert opinion of Pharmacotherapy. 2011. Vol.12. P.2411-2419. 76. Howland R.H. A benefit-risk assessment of agomelatine in the treatment of major depression // Drug Safety. 2011. Vol.34. P.709-731. 77. Абрамова Л.И., Новоженова Т.Е., Сорокин С.А. Вальдоксан (агомелатин): современный подход к лечению умеренных и тяжелых эндогенных депрессий непсихотического уровня // Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2011. № 3. C. 34-39. 78. Яхно Н.Н., Вознесенская Т.Г. Эффективность и переносимость агомелатина (Вальдоксан) при терапии легких и умеренных депрессивных расстройств в неврологической практике (результаты российского мультицентрового исследования «Камертон») // Неврологический журнал. 2012. Т.17. №1. С.43-49. 79. Cardinali D.P., Hardeland R. Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies // Neuroendocrinology. 2017. Vol.104. P.382–397. 80. Kennedy S.H. Favorable sexual profile of agomelatine in depressed patients // Eur. Neuropsychopharmacol. 2006. Vol.16. P.319-320. 81. Kennedy S.H., Rizvi S., Fulton K. et al. A Double-blind comparison of sexual functioning, antidepressant efficacy and tolerability between agomelatine and venlafaxine XR // J. Clin. Psychopharmacol. 2008. Vol.28. P.329-333. 82. Montejo A.L., Prieto N., Terleira A. et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale // J. Psychopharmacol. 2010. Vol.24. N.1. P.111-120. 83. Sapetti A. Agomelatine: an antidepressant without deterioration of sexual response // J. Sex Marital Ther. 2012. Vol.38. N.2. P.190-197.